1
Clinical Trials associated with TR-004A First in Human Feasibility Study of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion
Crohn's Disease (CD) is a condition that causes inflammation of the digestive system or gut. Crohn's can affect any part of the gut, though the most common area affected is the end of the ileum (the last part of the small intestine), or the colon.
Crohn's is a chronic condition. This means that it is ongoing and life-long, although patients may have periods of good health (remission), as well as times when symptoms are more active (relapses or flare-ups).
Current available therapies frequently fail to maintain long-term remission and may be complicated by significant side effects.
There is an unmet medical need for novel therapies. Cellular therapies are emerging as potentially attractive therapeutic strategies.
The TRIBUTE trial will use autologous regulatory T cells (Tregs) expanded in vitro.
It is hoped that the administration of this treatment to patients with active CD will change the immune responses in the gut and reduce bowel wall inflammation.
100 Clinical Results associated with TR-004
100 Translational Medicine associated with TR-004
100 Patents (Medical) associated with TR-004
100 Deals associated with TR-004